1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2017;71(1):96-108. 
2. Casilla-Lennon MM, Choi SK, Deal AM, Bensen JT, Narang G, Filippou P, et al. Financial Toxicity among Patients with Bladder Cancer: Reasons for Delay in Care and Effect on Quality of Life. J Urol. 2018;199(5):1166-73. 
3. Siegel S, Noblett K, Mangel J, Bennett J, Griebling TL, Sutherland SE, et al. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation. J Urol. 2018;199(1):229-36. 
4. Park S, Jee SH, Shin HR, Park EH, Shin A, Jung KW, et al. Attributable fraction of tobacco smoking on cancer using population-based nationwide cancer incidence and mortality data in Korea. BMC Cancer. 2014;14(1):406. 
5. Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA. 2014;311(2):183-92. 
6. Moolgavkar SH, Stevens RG. Smoking and cancers of bladder and pancreas: risks and temporal trends. J Natl Cancer Inst. 1981;67(1):15-23. 
7. Eriksen M, Mackay J, Schluger N, Islami Gomeshtapeh F, Drope J. The tobacco atlas. 5th ed. New York: American Cancer Society; 2015. 
8. Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011;103(24):1827-39. 
9. Steinmaus C, Miller MD, Cushing L, Blount BC, Smith AH. Combined effects of perchlorate, thiocyanate, and iodine on thyroid function in the National Health and Nutrition Examination Survey 2007-08. Environ Res. 2013;123:17-24. 
10. Antonova O, Toncheva D, Grigorov E. Bladder cancer risk from the perspective of genetic polymorphisms in the carcinogen metabolizing enzymes. J BUON. 2015;20(6):1397-406. 
11. Jost SP, Gosling JA, Dixon JS. The morphology of normal human bladder urothelium. J Anat. 1989;167:103-15. 
12. Ovčak Z. Klasifikacija urotelnih tumorjev sečnega mehurja WHO/ISUP (WHO/ISUP classification of the urothelial tumors of the urinary bladder). Zdr Vestn. 2005;74:529-33. 
13. Mertens LS, Neuzillet Y, Horenblas S, van Rhijn BW. Landmarks in non-muscle-invasive bladder cancer. Nat Rev Urol. 2014;11(8):476-80. 
14. Epstein JI, Amin MB, Reuter VR, Mostofi FK; Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22(12):1435-48. 
15. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al.; European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639-53. 
16. Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int. 2008;102(9b):1242-6. 
17. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176(6 Pt 1):2414-22. 
18. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK; International Collaboration of Trialists; et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171-7. 
19. Nomura S, Suzuki Y, Takahashi R, Terasaki M, Kimata R, Hamasaki T, et al. Snail expression and outcome in T1 high-grade and T2 bladder cancer: a retrospective immunohistochemical analysis. BMC Urol. 2013;13(1):73. 
20. Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006;24(3):296-304. 
21. Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013;37(3):219-25. 
22. DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643-53. 
23. Ghosh M, Brancato SJ, Agarwal PK, Apolo AB. Targeted therapies in urothelial carcinoma. Curr Opin Oncol. 2014;26(3):305-20. 
24. Gerlinger M, Catto JW, Orntoft TF, Real FX, Zwarthoff EC, Swanton C. Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications. Eur Urol. 2015;67(4):729-37. 
25. Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res. 2009;69(23):8958-66. 
26. Kreft ME, Hudoklin S, Sterle M. Establishment and characterization of primary and subsequent subcultures of normal mouse urothelial cells. Folia Biol (Praha). 2005;51(5):126-32. 
27. Višnjar T, Kocbek P, Kreft ME. Hyperplasia as a mechanism for rapid resealing urothelial injuries and maintaining high transepithelial resistance. Histochem Cell Biol. 2012;137(2):177-86. 
28. Masters JR, Petzoldt JL. In vitro studies on the pathogenesis of bladder cancer. Verh Dtsch Ges Pathol. 1993;77:157-60. 
29. van Kessel KE, Zuiverloon TC, Alberts AR, Boormans JL, Zwarthoff EC. Targeted therapies in bladder cancer: an overview of in vivo research. Nat Rev Urol. 2015;12(12):681-94. 
30. Sens DA, Park S, Gurel V, Sens MA, Garrett SH, Somji S. Inorganic cadmium- and arsenite-induced malignant transformation of human bladder urothelial cells. Toxicol Sci. 2004;79(1):56-63. 
31. DeBerardinis RJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell. 2012;148(6):1132-44. 
32. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 1998-1999;17(3):279-84. 
33. Kyker KD, Culkin DJ, Hurst RE. A model for 3-dimensional growth of bladder cancers to investigate cell-matrix interactions. Urol Oncol. 2003;21(4):255-61. 
34. Resnik N, Prezelj T, De Luca GM, Manders E, Polishchuk R, Veranič P, et al. Helical organization of microtubules occurs in a minority of tunneling membrane nanotubes in normal and cancer urothelial cells. Sci Rep. 2018;8(1):17133. 
35. Ogorevc E, Hudoklin S, Veranič P, Kralj-Iglič V. Extracellular vesicle-mediated transfer of membranous components from the highly malignant T24 urinary carcinoma cell line to the non-malignant RT4 urinary papilloma cell line. Protoplasma. 2014;251(3):699-702. 
36. Lainšček D, Kadunc L, Keber MM, Bratkovič IH, Romih R, Jerala R. Delivery of an Artificial Transcription Regulator dCas9-VPR by Extracellular Vesicles for Therapeutic Gene Activation. ACS Synth Biol. 2018;7(12):2715-25. 
37. Ibrahiem EH, Nigam VN, Brailovsky CA, Madarnas P, Elhilali M. Orthotopic implantation of primary N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide-induced bladder cancer in bladder submucosa: an animal model for bladder cancer study. Cancer Res. 1983;43(2):617-22. 
38. Günther JH, Jurczok A, Wulf T, Brandau S, Deinert I, Jocham D, et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res. 1999;59(12):2834-7. 
39. Clayson DB, Fishbein L, Cohen SM. Effects of stones and other physical factors on the induction of rodent bladder cancer. Food Chem Toxicol. 1995;33(9):771-84. 
40. Knapp DW, Henry CJ, Widmer WR, Tan KM, Moore GE, Ramos-Vara JA, et al. Randomized trial of cisplatin versus firocoxib versus cisplatin/firocoxib in dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med. 2013;27(1):126-33. 
41. Knapp DW, Ramos-Vara JA, Moore GE, Dhawan D, Bonney PL, Young KE. Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development. ILAR J. 2014;55(1):100-18. 
42. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006;66(7):3351-4. 
43. Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt AW, et al. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget. 2015;6(25):21522-32. 
44. Matsuo T, Miyata Y, Asai A, Sagara Y, Furusato B, Fukuoka J, et al. Green Tea Polyphenol Induces Changes in Cancer-Related Factors in an Animal Model of Bladder Cancer. PLoS One. 2017;12(1):e0171091. 
45. Slocum SL, Kensler TW. Nrf2: control of sensitivity to carcinogens. Arch Toxicol. 2011;85(4):273-84. 
46. Gofrit ON, Birman T, Dinaburg A, Ayesh S, Ohana P, Hochberg A. Chemically induced bladder cancer—a sonographic and morphologic description. Urology. 2006;68(1):231-5. 
47. Ariel I, Ayesh S, Gofrit O, Ayesh B, Abdul-Ghani R, Pizov G, et al. Gene expression in the bladder carcinoma rat model. Mol Carcinog. 2004;41(2):69-76. 
48. Bertram JS, Craig AW. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer. 1972;8(6):587-94. 
49. Kunze E, Chowaniec J. Pathology of tumours in laboratory animals. Tumours of the rat. Tumours of the urinary bladder. IARC Sci Publ. 1990(99):345-97. 
50. Okajima E, Hiramatsu T, Hirao K, Ijuin M, Hirao Y, Babaya K, et al. Urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in dogs. Cancer Res. 1981;41(5):1958-66. 
51. Vasconcelos-Nóbrega C, Colaço A, Lopes C, Oliveira PA. Review: BBN as an urothelial carcinogen. In Vivo. 2012;26(4):727-39. 
52. Tsuda H, Miyata Y, Hagiwara A, Hasegawa R, Shirai T, Ito N. Damage and repair of DNA in urinary bladder epithelium of rats treated with N-butyl-N-(4-hydroxybutyl) nitrosamine. Gan. 1977;68(6):781-3. 
53. Airoldi L, Magagnotti C, Bonfanti M, Fanelli R. Alpha-oxidative metabolism of the bladder carcinogens N-nitrosobutyl(4-hydroxybutyl)amine and N-nitrosobutyl(3-carboxypropyl)amine within the rat isolated bladder. Carcinogenesis. 1990;11(8):1437-40. 
54. Cohen SM, Ohnishi T, Clark NM, He J, Arnold LL. Investigations of rodent urinary bladder carcinogens: collection, processing, and evaluation of urine and bladders. Toxicol Pathol. 2007;35(3):337-47. 
55. Cohen SM. Urinary bladder carcinogenesis. Toxicol Pathol. 1998;26(1):121-7. 
56. Ohtani M, Kakizoe T, Nishio Y, Sato S, Sugimura T, Fukushima S, et al. Sequential changes of mouse bladder epithelium during induction of invasive carcinomas by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res. 1986;46(4 Pt 2):2001-4. 
57. Zupančič D, Ovčak Z, Vidmar G, Romih R. Altered expression of UPIa, UPIb, UPII, and UPIIIa during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats. Virchows Arch. 2011;458(5):603-13. 
58. Zupančič D, Kreft ME, Romih R. Selective binding of lectins to normal and neoplastic urothelium in rat and mouse bladder carcinogenesis models. Protoplasma. 2014;251(1):49-59. 
59. Chan ES, Patel AR, Smith AK, Klein JB, Thomas AA, Heston WD, et al. Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model. J Urol. 2009;182(6):2926-31. 
60. Sengeløv L, Kamby C, von der Maase H. Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma. J Urol. 1996;155(1):111-4. 
61. Xiao Z, McCallum TJ, Brown KM, Miller GG, Halls SB, Parney I, et al. Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer. 1999;81(4):638-46. 
62. Marks P, Soave A, Shariat SF, Fajkovic H, Fisch M, Rink M. Female with bladder cancer: what and why is there a difference? Transl Androl Urol. 2016;5(5):668-82. 
63. Erman A, Kapun G, Novak S, Pavlin M, Dražić G, Drobne D, et al. How cancer cells attach to urinary bladder epithelium in vivo: study of the early stages of tumorigenesis in an orthotopic mouse bladder tumor model. Histochem Cell Biol. 2019;151(3):263-73. 
64. Abate-Shen C, Pandolfi PP. Effective utilization and appropriate selection of genetically engineered mouse models for translational integration of mouse and human trials. Cold Spring Harb Protoc. 2013;2013(11):pdb.top078774. 
65. Kobayashi T, Owczarek TB, McKiernan JM, Abate-Shen C. Modelling bladder cancer in mice: opportunities and challenges. Nat Rev Cancer. 2015;15(1):42-54. 
66. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-22. 
67. Wu XR, Lin JH, Walz T, Häner M, Yu J, Aebi U, et al. Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem. 1994;269(18):13716-24. 
68. Wu XR, Manabe M, Yu J, Sun TT. Large scale purification and immunolocalization of bovine uroplakins I, II, and III. Molecular markers of urothelial differentiation. J Biol Chem. 1990;265(31):19170-9. 
69. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 1999;59(14):3512-7. 
70. Ayala de la Peña F, Kanasaki K, Kanasaki M, Tangirala N, Maeda G, Kalluri R. Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem. 2011;286(23):20778-87. 
71. Stone R, Sabichi AL, Gill J, Lee IL, Adegboyega P, Dai MS, et al. Identification of genes correlated with early-stage bladder cancer progression. Cancer Prev Res (Phila). 2010;3(6):776-86. 
72. Wu XR. Biology of urothelial tumorigenesis: insights from genetically engineered mice. Cancer Metastasis Rev. 2009;28(3-4):281-90. 
73. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 2009;23(6):675-80. 
74. Ramesh N, Memarzadeh B, Ge Y, Frey D, VanRoey M, Rojas V, et al. Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium. Mol Ther. 2004;10(4):697-705. 
75. Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J, et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila). 2009;2(12):1008-14. 
76. Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J. 1997;14(5):569-76. 
77. Višnjar T, Romih R, Zupančič D. Lectins as possible tools for improved urinary bladder cancer management. Glycobiology. 2019;29(5):355-65. 
78. Zupančič D, Kreft ME, Grdadolnik M, Mitev D, Iglič A, Veranič P. Detonation nanodiamonds are promising nontoxic delivery system for urothelial cells. Protoplasma. 2018;255(1):419-23. 
79. Imani R, Veranič P, Iglič A, Kreft ME, Pazoki M, Hudoklin S. Combined cytotoxic effect of UV-irradiation and TiO2 microbeads in normal urothelial cells, low-grade and high-grade urothelial cancer cells. Photochem Photobiol Sci. 2015;14(3):583-90. 
80. Erman A, Veranič P. The Use of Polymer Chitosan in Intravesical Treatment of Urinary Bladder Cancer and Infections. Polymers (Basel). 2018;10(3):E265. 
